These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33833384)

  • 1. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
    Batta K; Bossenbroek HM; Pemmaraju N; Wilks DP; Chasty R; Dennis M; Milne P; Collin M; Beird HC; Taylor J; Patnaik MM; Cargo CA; Somervaille TCP; Wiseman DH
    Leukemia; 2021 Nov; 35(11):3299-3303. PubMed ID: 33833384
    [No Abstract]   [Full Text] [Related]  

  • 2. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin.
    Brunetti L; Di Battista V; Venanzi A; Schiavoni G; Martelli MP; Ascani S; Mecucci C; Tiacci E; Falini B
    Leukemia; 2017 May; 31(5):1238-1240. PubMed ID: 28111467
    [No Abstract]   [Full Text] [Related]  

  • 3. Blastic plasmacytoid dendritic cell neoplasm with a history of cytopenia: A case report.
    Yan M; Wang W; Cen X; Wang L; Sun Y; Wang B; Ou J; Nong L; Ren H; Zhu P; Wang M
    Diagn Cytopathol; 2020 Nov; 48(11):1102-1106. PubMed ID: 32374950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.
    Patnaik MM; Lasho T; Howard M; Finke C; Ketterling RL; Al-Kali A; Pardanani A; Droin N; Gangat N; Tefferi A; Solary E
    Blood Cancer J; 2018 Aug; 8(9):82. PubMed ID: 30190511
    [No Abstract]   [Full Text] [Related]  

  • 5. Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone.
    Denker S; Künstner A; Schwarting J; Witte HM; Bernard V; Stölting S; Lohneis P; Kusch K; von Bubnoff N; Merz H; Busch H; Feller AC; Gebauer N
    Leukemia; 2024 Aug; 38(8):1858-1861. PubMed ID: 38890446
    [No Abstract]   [Full Text] [Related]  

  • 6. Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis.
    Suma S; Sakata-Yanagimoto M; Nguyen TB; Hattori K; Sato T; Noguchi M; Nannya Y; Ogawa S; Watanabe R; Fujimoto M; Nakamura N; Kusakabe M; Nishikii H; Kato T; Chiba S
    Int J Hematol; 2018 Oct; 108(4):447-451. PubMed ID: 29705980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review.
    Espasa A; Sorigue M; Tapia G; Cabezon M; Vergara S; Raya M; Navarro JT; Junca J; Zamora L; Xicoy B
    Cytometry B Clin Cytom; 2021 May; 100(3):292-295. PubMed ID: 32830878
    [No Abstract]   [Full Text] [Related]  

  • 8. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.
    Jardin F; Ruminy P; Parmentier F; Troussard X; Vaida I; Stamatoullas A; Leprêtre S; Penther D; Duval AB; Picquenot JM; Courville P; Capiod JC; Tilly H; Bastard C; Marolleau JP
    Br J Haematol; 2011 May; 153(3):413-6. PubMed ID: 21275969
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
    Khanlari M; Yin CC; Takahashi K; Lachowiez C; Tang G; Loghavi S; Bah I; Wang W; Konoplev S; Medeiros LJ; Pemmaraju N; Khoury JD; Wang SA
    Leukemia; 2022 May; 36(5):1343-1350. PubMed ID: 35279700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent Aortic Thromboembolism Associated With
    Bukhari S; Saati A; Abuhalimeh B; Ouma G
    J Investig Med High Impact Case Rep; 2024; 12():23247096231224366. PubMed ID: 38214069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia.
    Hu Z; Sun T
    Blood; 2016 Sep; 128(12):1664. PubMed ID: 28092882
    [No Abstract]   [Full Text] [Related]  

  • 12. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases.
    Vitte F; Fabiani B; Bénet C; Dalac S; Balme B; Delattre C; Vergier B; Beylot-Barry M; Vignon-Pennamen D; Ortonne N; Algros MP; Carlotti A; Samaleire D; Frouin E; Levy A; Laroche L; Theate I; Monnien F; Mugneret F; Petrella T
    Am J Surg Pathol; 2012 Sep; 36(9):1302-16. PubMed ID: 22895265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoplasms derived from plasmacytoid dendritic cells.
    Facchetti F; Cigognetti M; Fisogni S; Rossi G; Lonardi S; Vermi W
    Mod Pathol; 2016 Feb; 29(2):98-111. PubMed ID: 26743477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival.
    Shimony S; Keating J; Fay CJ; Luskin MR; Neuberg DS; LeBoeuf NR; Lane AA
    Blood Adv; 2024 Jun; 8(11):2803-2812. PubMed ID: 38603567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia.
    Garcia-Gisbert N; Arenillas L; Roman-Bravo D; Rodriguez-Sevilla JJ; Fernández-Rodríguez C; Garcia-Avila S; Velez P; Gibert J; Fernández-Ibarrondo L; Salar A; Florensa L; Bellosillo B; Ferrer A; Calvo X
    Leukemia; 2022 Dec; 36(12):2922-2926. PubMed ID: 36273104
    [No Abstract]   [Full Text] [Related]  

  • 19. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelomonocytic leukaemia followed by blastic plasmacytoid dendritic cell neoplasm.
    Lebecque B; Vial JP; Pigneux A; Lechevalier N
    Br J Haematol; 2019 May; 185(3):398. PubMed ID: 30784042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.